Cargando…
631. Using a commercially available assay that measures cytomegalovirus (CMV)-specific CD4+ and CD8+ T-cell immunity to predict protection against CMV: Results from a prospective, blinded clinical trial
BACKGROUND: Cytomegalovirus (CMV) infection is associated with significant morbidity and mortality among kidney transplant recipients (KTR). Given toxicities and costs of antivirals, there is growing interest in assays that measure CMV-specific T-cell immunity (TCI), which may predict protection aga...
Autores principales: | Almaghlouth, Nouf K, Arvanitis, Panos, Vieira, Kendra, Farmakiotis, Dimitrios |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678232/ http://dx.doi.org/10.1093/ofid/ofad500.697 |
Ejemplares similares
-
2082. Using a Commercially Available Assay Measuring Cytomegalovirus (CMV)-Specific CD4+ and CD8+ T-Cell Immunity by Intracellular Cytokine Staining to Predict Clinically Significant CMV Events
por: Rogers, Ralph, et al.
Publicado: (2018) -
Clinical experience with a novel assay measuring cytomegalovirus (CMV)-specific CD4+ and CD8+ T-cell immunity by flow cytometry and intracellular cytokine staining to predict clinically significant CMV events
por: Rogers, Ralph, et al.
Publicado: (2020) -
Correction to: Clinical experience with a novel assay measuring cytomegalovirus (CMV)-specific CD4+ and CD8+ T-cell immunity by flow cytometry and intracellular cytokine staining to predict clinically significant CMV events
por: Rogers, Ralph, et al.
Publicado: (2020) -
Outpatient anti-spike monoclonal antibody administration is associated with decreased morbidity and mortality among patients with cancer and COVID-19
por: Arvanitis, Panos, et al.
Publicado: (2023) -
Outpatient anti-spike monoclonal antibody administration is associated with decreased morbidity and mortality among patients with cancer and COVID-19
por: Arvanitis, Panos, et al.
Publicado: (2023)